Evolution of 18F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation

J Nucl Med. 2022 Feb;63(2):270-273. doi: 10.2967/jnumed.121.262296. Epub 2021 Jul 16.

Abstract

The aim of this study was to assess the temporal evolution of pulmonary 18F-FDG uptake in patients with coronavirus disease 2019 (COVID-19) and post-COVID-19 lung disease (PCLD). Methods: Using our hospital's clinical electronic records, we retrospectively identified 23 acute COVID-19, 18 PCLD, and 9 completely recovered 18F-FDG PET/CT patients during the 2 peaks of the U.K. pandemic. Pulmonary 18F-FDG uptake was measured as a lung target-to-background ratio (TBRlung = SUVmax/SUVmin) and compared with temporal stage. Results: In acute COVID-19, less than 3 wk after infection, TBRlung was strongly correlated with time after infection (rs = 0.81, P < 0.001) and was significantly higher in the late stage than in the early stage (P = 0.001). In PCLD, TBRlung was lower in patients treated with high-dose steroids (P = 0.003) and in asymptomatic patients (P < 0.001). Conclusion: Pulmonary 18F-FDG uptake in COVID-19 increases with time after infection. In PCLD, pulmonary 18F-FDG uptake rises despite viral clearance, suggesting ongoing inflammation. There was lower pulmonary 18F-FDG uptake in PCLD patients treated with steroids.

Keywords: 18F-FDG; COVID-19; PET/CT; infectious disease; respiratory.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • COVID-19 / diagnostic imaging*
  • Female
  • Fluorodeoxyglucose F18 / pharmacokinetics*
  • Humans
  • Lung / diagnostic imaging*
  • Male
  • Middle Aged
  • Positron Emission Tomography Computed Tomography / methods*
  • Radiopharmaceuticals / pharmacokinetics*
  • Retrospective Studies
  • SARS-CoV-2*
  • Young Adult

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18